OsteoRemedies announced FDA clearance for expanded indications for SPECTRUM GV Bone Cement. The expanded indication covers the fixation of revision hip arthroplasty components, implanted in the second stage of a two-stage revision after the initial infection has been cleared.
Initially launched in 2018, SPECTRUM GV Bone Cement is reportedly the first commercially available dual antibiotic bone cement on the US market. Containing both vancomycin and gentamicin, SPECTRUM GV Bone Cement prevents bacterial adhesion of susceptible organisms, intermediate-resistant and methicillin-resistant staphylococcal infections.
From a mechanical performance perspective, testing of SPECTRUM GV Bone Cement has been compared to commercially available single antibiotic bone cements and found to have substantially equivalent mechanical integrity. The mechanical performance enables its use beyond the original indication, as highlighted by Dr. Michael Meneghini, M.D. and CEO of Indiana Joint Replacement Institute.
When asked about the unique value SPECTRUM GV Bone Cement brings to joint revision patients, Dr. Meneghini commented, “Revision hip and knee arthroplasty patients are increasingly at high risk for MRSA. Vancomycin coverage in the cement provides added protection against PJI in those high risk patients.”
OsteoRemedies announced FDA clearance for expanded indications for SPECTRUM GV Bone Cement. The expanded indication covers the fixation of revision hip arthroplasty components, implanted in the second stage of a two-stage revision after the initial infection has been cleared.
OsteoRemedies announced FDA clearance for expanded indications for SPECTRUM GV Bone Cement. The expanded indication covers the fixation of revision hip arthroplasty components, implanted in the second stage of a two-stage revision after the initial infection has been cleared.
Initially launched in 2018, SPECTRUM GV Bone Cement is reportedly the first commercially available dual antibiotic bone cement on the US market. Containing both vancomycin and gentamicin, SPECTRUM GV Bone Cement prevents bacterial adhesion of susceptible organisms, intermediate-resistant and methicillin-resistant staphylococcal infections.
From a mechanical performance perspective, testing of SPECTRUM GV Bone Cement has been compared to commercially available single antibiotic bone cements and found to have substantially equivalent mechanical integrity. The mechanical performance enables its use beyond the original indication, as highlighted by Dr. Michael Meneghini, M.D. and CEO of Indiana Joint Replacement Institute.
When asked about the unique value SPECTRUM GV Bone Cement brings to joint revision patients, Dr. Meneghini commented, “Revision hip and knee arthroplasty patients are increasingly at high risk for MRSA. Vancomycin coverage in the cement provides added protection against PJI in those high risk patients.”
Copy to clipboard 
